Extracellular small non-coding RNA contaminants in fetal bovine serum and serum-free media.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
02 04 2019
Historique:
received: 07 10 2018
accepted: 18 03 2019
entrez: 4 4 2019
pubmed: 4 4 2019
medline: 6 10 2020
Statut: epublish

Résumé

In the research field of extracellular vesicles (EVs), the use of fetal bovine serum (FBS) depleted of EVs for in vitro studies is advocated to eliminate the confounding effects of media derived EVs. EV-depleted FBS may either be prepared by ultracentrifugation or purchased commercially. Nevertheless, these preparations do not guarantee an RNA-free FBS for in vitro use. In this study we address the RNA contamination issue, of small non-coding (nc)RNA in vesicular or non-vesicular fractions of FBS, ultracentrifugation EV-depleted FBS, commercial EV-depleted FBS, and in our recently developed filtration based EV-depleted FBS. Commercially available serum- and xeno-free defined media were also screened for small ncRNA contamination. Our small ncRNA sequencing data showed that all EV-depleted media and commercially available defined media contained small ncRNA contaminants. Out of the different FBS preparations studied, our ultrafiltration-based method for EV depletion performed the best in depleting miRNAs. Certain miRNAs such miR-122 and miR-203a proved difficult to remove completely and were found in all media. Compared to miRNAs, other small ncRNA (snRNA, Y RNA, snoRNA, and piRNA) were difficult to eliminate from all the studied media. Additionally, our tested defined media contained miRNAs and other small ncRNAs, albeit at a much lower level than in serum preparations. Our study showed that no media is free of small ncRNA contaminants. Therefore, in order to screen for baseline RNA contamination in culturing media, RNA sequencing data should be carefully controlled by adding a media sample as a control. This should be a mandatory step before performing cell culture experiments in order to eliminate the confounding effects of media.

Identifiants

pubmed: 30940830
doi: 10.1038/s41598-019-41772-3
pii: 10.1038/s41598-019-41772-3
pmc: PMC6445286
doi:

Substances chimiques

Culture Media, Serum-Free 0
MicroRNAs 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5538

Commentaires et corrections

Type : ErratumIn

Références

Elife. 2015 Jul 23;4:
pubmed: 26203562
Circ Res. 2017 May 12;120(10):1632-1648
pubmed: 28495994
Stem Cell Res. 2017 Oct;24:164-168
pubmed: 29034887
Nat Cell Biol. 2011 Apr;13(4):423-33
pubmed: 21423178
Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):5003-8
pubmed: 21383194
BMC Biotechnol. 2016 Apr 02;16:32
pubmed: 27038912
Nucleic Acids Res. 2018 Jan 4;46(D1):D354-D359
pubmed: 29036351
Cell Death Dis. 2013 Feb 28;4:e514
pubmed: 23449450
J Biol Chem. 2011 Nov 4;286(44):38211-9
pubmed: 21896489
J Extracell Vesicles. 2018 Jun 04;7(1):1481321
pubmed: 29887978
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
Sci Rep. 2016 Aug 09;6:31175
pubmed: 27503761
Int J Mol Sci. 2013 Mar 06;14(3):5338-66
pubmed: 23466882
Bioinformatics. 2015 Mar 15;31(6):933-9
pubmed: 25388151
Nat Rev Immunol. 2009 Aug;9(8):581-93
pubmed: 19498381
J Transl Med. 2011 Jan 14;9:9
pubmed: 21235781
J Extracell Vesicles. 2018 Jan 21;7(1):1422674
pubmed: 29410778
Sci Rep. 2016 Jul 04;6:28301
pubmed: 27376958
Nat Med. 1998 May;4(5):594-600
pubmed: 9585234
FASEB J. 2015 Apr;29(4):1435-45
pubmed: 25550459
Sci Rep. 2018 Oct 19;8(1):15503
pubmed: 30341351
Adv Exp Med Biol. 2013;786:329-51
pubmed: 23696365
J Extracell Vesicles. 2015 Mar 26;4:26373
pubmed: 25819213
J Extracell Vesicles. 2014 Sep 30;3:
pubmed: 25317276
Eur J Pharm Sci. 2017 Feb 15;98:30-39
pubmed: 27771514
Oncol Lett. 2018 Feb;15(2):2695-2699
pubmed: 29434994
Biomed Res Int. 2018 Jan 30;2018:8545347
pubmed: 29662902
J Cell Biol. 1999 Nov 1;147(3):599-610
pubmed: 10545503
ALTEX. 2010;27(1):53-62
pubmed: 20390239
Nucleic Acids Res. 2011 Sep 1;39(16):7223-33
pubmed: 21609964
PLoS One. 2017 Jan 23;12(1):e0170628
pubmed: 28114422

Auteurs

Bettina Mannerström (B)

Department of Oral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Riku O Paananen (RO)

Helsinki Eye Lab, Ophthalmology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Ahmed G Abu-Shahba (AG)

Department of Oral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Tanta University, Tanta, Egypt.

Jukka Moilanen (J)

Helsinki Eye Lab, Ophthalmology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Riitta Seppänen-Kaijansinkko (R)

Department of Oral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Sippy Kaur (S)

Department of Oral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. sippy.kaur@helsinki.fi.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH